RA CAPITAL MANAGEMENT, L.P. purchased $7.7M of ARTV (indirect holdings)
RA CAPITAL MANAGEMENT, L.P. purchased 1,027,722 indirectly-held shares of Artiva Biotherapeutics, Inc. (ARTV) at an average of $7.44 ($6.91–$7.91, $7.65M total) across 3 trades over 2026-06-09 to 2026-06-11.
How this was made
The 30-second read
Why it matters
The newest concrete fact is the disclosed open-market purchase size, price range, and resulting holdings after the trades.
Market read
Traders may treat the filing as a modest sentiment tailwind, but without new clinical/regulatory/financial catalysts it is unlikely to be a primary driver.
What to watch
The article lacks context on prior stake changes, valuation, and whether the buy coincided with any contemporaneous news or price dislocation.
Background
This is an SEC Form 4 insider transaction disclosure (RA Capital Management, L.P.) for Artiva Biotherapeutics, Inc.
Ticker impact
RA Capital Management (10% owner/director) bought 1,027,722 shares of Artiva Biotherapeutics via open-market purchases totaling ~$7.65M (Form 4).
Near-term impact likely limited; may provide modest support to sentiment/positioning rather than drive a repricing.
Form 4 insider/institutional buying can influence sentiment, yet the article provides no new operational/clinical/regulatory information—only transaction details and post-trade share count.
Market effects
Minimal; this is company-specific ownership activity with no stated sector-wide signal.
None indicated.
None indicated.
Counterpoint
A large buy can be driven by pre-existing plans, liquidity needs, or portfolio rebalancing rather than a new positive thesis (note: no 10b5-1 plan is stated).
Key entities
- issuerArtiva Biotherapeutics, Inc.
Subject of the Form 4 insider transaction; RA Capital Management increased holdings via open-market buys.
- insider/10% ownerRA Capital Management, L.P.
Reporter on the Form 4; executed purchases totaling ~$7.65M across three trades.